舒泰神：STSA-1002注射液具有良好的安全性和耐受性

Core Viewpoint - The company Shuyou Shen announced that its STSA-1002 injection has demonstrated good safety and tolerability in patients with acute respiratory distress syndrome, based on the summary report of the Phase Ib/II clinical study [1] Summary by Relevant Sections - Clinical Study Results - The primary endpoint indicators showed that both dosage groups had shorter durations compared to the control group [1] - The secondary endpoint indicators for the 28-day all-cause mortality rate were as follows: low-dose group at 26.67%, high-dose group at 5.88%, and control group at 40.00% [1] - Safety and Tolerability - STSA-1002 injection is reported to have good safety and tolerability [1]